5/21/2010

The risk of multiple myeloma progression was reduced by more than 50% in stem cell transplant patients who received Celgene's Revlimid as maintenance therapy, two studies showed. One of the clinical trials also noted an 88% survival rate for Revlimid patients after three years, compared with 80% in the group that took a placebo.

Full Story:
Reuters

Related Summaries